PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy1 citations

Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma

View Full Paper
MMMilre M. MatherneJPJohn C. PanettaJHJaclyn Hopp

Key Points

  • This study examines how adherence to dosing intervals affects pharmacokinetics of asparaginase in children with leukemia or lymphoma.
  • Evaluation of dosing schedule adherence among pediatric patients
  • Assessment of asparaginase pharmacokinetic outcomes
  • Comparison of outcomes based on adherence to FDA guidelines
  • Greater adherence to dosing intervals correlates with improved asparaginase activity
  • Non-adherence linked to reduced effectiveness in treatment
  • Supports FDA guidelines for dosing in pediatric cancer patients

Abstract

Overall, our findings support the importance of adhering closely to the United States Food and Drug Administration approved dosing schedule for R-ASP to ensure adequate asparaginase activity in pediatric patients with leukemia or lymphoma.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Matherne et al. (2026) studied this question.

synapsesocial.com/papers/69e9ba2a85696592c86ec896https://doi.org/10.1002/phar.70146
Ask AI
Helpful
Bookmark
Share
View Full Paper